Regeneron Pharmaceuticals, Inc.
REGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000872589
In the last 90 days, Regeneron Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 1,342 institutions reported holding it in 13F filings for Q2 2026, worth $57.1B in total; Southeastern Asset Management (Longleaf) is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Regeneron Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 1,196 | 8 | 1,168 | −20 |
| Shares | 99.1M | 25.6K | 92.6M | −6.46M (−6.5%) |
| Value | $76.1B | $21.1M | $66.2B | −$9.92B (−13.0%) |
8 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (88)
Institutions that held Regeneron Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (108)
Institutions that held Regeneron Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Showing the largest 100 of 108 by value.
Not filed for Q2 2023 yet (8)
Institutions that held Regeneron Pharmaceuticals, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Avalon Investment & Advisory | 13,831 | $11.4M |
| Parsec Financial Management, Inc. | 9,928 | $8.16M |
| HNP Capital LLC | 1,118 | $918.6K |
| ETF Managers Group, LLC | 432 | $355.0K |
| Euclidean Technologies Management, LLC | 263 | $216.1K |
| Householder Group Estate & Retirement Specialist, LLC | 37 | $30.0K |
| Ahrens Investment Partners LLC | 15 | $12.3K |
| Baldrige Asset Management LLC | 1 | $1.00K |